Your browser doesn't support javascript.
Developing a COVID-19 Yeast Oral Vaccine for Low Income Countries
Journal of Biological Chemistry ; 299(3 Supplement):S134, 2023.
Article in English | EMBASE | ID: covidwho-2313221
ABSTRACT
The novel COVID-19 vaccines have been instrumental at transforming the pandemic into an endemic disease. However, many contemporary vaccines, especially the landmark mRNA vaccines, require cold storage that makes them difficult for low income and developing countries to keep and distribute, and no shelf stable, low-cost alternative currently exists. In response to this need, we are developing a novel COVID-19 vaccine delivery system using the probiotic yeast Saccharomyces boulardii. We engineered an integrating construct to express the receptor binding domain (RBD) of the SARS-CoV-2 spike protein tagged with the yeast pheromone secretion signal and with the Claudin-4 targeting sequence of the Clostridium perfringens enterotoxin. Preliminary data from two animal trials suggest that our candidate yeast oral COVID-19 vaccine can trigger a robust humoral immune response in mice. Experiments are underway to assess its effect on the murine T-cell response. Our laboratory is supported in part by a research grant from the PCHRD-DOST of the Republic of the Philippines.Copyright © 2023 The American Society for Biochemistry and Molecular Biology, Inc.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Journal of Biological Chemistry Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Journal of Biological Chemistry Year: 2023 Document Type: Article